Related Experiment Video
Updated: Aug 3, 2026
11:02
Vagus Nerve Stimulation as a Tool to Induce Plasticity in Pathways Relevant for Extinction Learning
Published on: August 21, 2015
Vagus nerve stimulation for refractory idiopathic generalised epilepsy
1Department of Neurology, NYU School of Medicine, New York, NY, USA.
Seizure
|March 11, 2004
Summary
Vagus nerve stimulation (VNS) effectively reduced seizure frequency in patients with medically refractory epilepsy. This therapy showed particular promise for those with idiopathic generalized epilepsy (IGE), aiding in seizure control and reduced medication needs.
Area of Science:
- Neurology
- Neurosurgery
- Epileptology
Background:
- Epilepsy is a chronic neurological disorder characterized by recurrent seizures.
- Medically refractory epilepsy poses significant treatment challenges.
- Vagus nerve stimulation (VNS) is an established neuromodulation therapy for epilepsy.
Purpose of the Study:
- To evaluate the efficacy of VNS in patients with medically refractory epilepsy.
- To assess seizure reduction and antiepileptic drug (AED) regimen changes with VNS therapy.
- To determine VNS effectiveness across different epilepsy types: partial epilepsy (PE), symptomatic generalized epilepsy (SGE), and idiopathic generalized epilepsy (IGE).
Main Methods:
- Retrospective review of 165 patients with medically refractory epilepsy undergoing VNS therapy.
- Analysis of seizure frequency reduction and changes in AED regimens.
- Stratification of results based on epilepsy type (PE, SGE, IGE).
Main Results:
- A significant reduction in seizure frequency (≥50%) was observed in 47.1% of PE, 46.1% of SGE, and 57.1% of IGE patients.
- Combined seizure reduction and reduced AED regimen occurred in 9.4% of PE, 7.7% of SGE, and 35.7% of IGE patients.
- VNS therapy demonstrated notable efficacy in improving seizure control for patients with IGE.
Conclusions:
- Vagus nerve stimulation is a viable treatment option for medically refractory epilepsy.
- VNS shows promising efficacy, particularly for patients with idiopathic generalized epilepsy.
- Further research is warranted to optimize VNS therapy for diverse epilepsy populations.
Related Concept Videos
01:13Seizures: Classification
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...